SIRPant Immunotherapeutics Overview
- Founded
-
2020

- Status
-
Private
- Employees
-
5

- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$25M
- Investors
-
3
SIRPant Immunotherapeutics General Information
Description
Developer of cancer-specific immunotherapy intended for the treatment of solid tumors. The company employs an Adoptive Cell Therapy (ACT) approach to elicit tumor-specific T-cells resulting in a polyclonal immune response against multiple tumor antigens, enabling the medical community to improve treatment outcomes related to cancer.
Contact Information
Website
www.sirpantimmunotx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Biotechnology
Primary Office
- 1214 Research Boulevard
- Suite 2010
- Hummelstown, PA 17036
- United States
+1 (610) 000-0000
SIRPant Immunotherapeutics Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
1. Early Stage VC (Series A) | 29-Sep-2021 | $25M | 0000 | 0000 | Completed | Generating Revenue |
SIRPant Immunotherapeutics Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series A | 0,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.00 |
SIRPant Immunotherapeutics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of cancer-specific immunotherapy intended for the treatment of solid tumors. The company employs an Adoptive C
Drug Discovery
Hummelstown, PA
5
As of 2022
0000
000
0000-00-00
00000000000
0000
SIRPant Immunotherapeutics Competitors (8)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Carisma Therapeutics | Venture Capital-Backed | Philadelphia, PA | 00 | 00000 | 00000000000 | 00000 |
0000 00000000 | Venture Capital-Backed | Brisbane, CA | 00 | 00000 | 00000000000 | 00000 |
000 00000000 | Formerly VC-backed | Burlingame, CA | 00 | 00000 | 00000000 | 00000 |
0000000000 000000 | Venture Capital-Backed | Windsor, United Kingdom | 0 | 000.00 | 0000000000 0 | 000.00 |
0000000 0000000000 | Venture Capital-Backed | Bedford, MA | 00 | 000.00 | 0000000000 0 | 000.00 |
SIRPant Immunotherapeutics Executive Team (5)
SIRPant Immunotherapeutics Board Members (3)
Name | Representing | Role | Since |
---|---|---|---|
John Fucci | Bios Partners | Board Member | 000 0000 |
Rifat Pamukcu MD | Self | Board Member | 000 0000 |
Travis Whitfull | Self | Board Member | 000 0000 |
SIRPant Immunotherapeutics Signals
SIRPant Immunotherapeutics Investors (3)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
BioAdvance | Venture Capital | Minority | 000 0000 | 000000 0 | |
Bios Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
GRA Venture Fund | Venture Capital | Minority | 000 0000 | 000000 0 |